Sigma-Chemist Warehouse deal secures ACCC approval
Sigma Healthcare (ASX:SIG) has announced that its proposed merger with Chemist Warehouse Group is not opposed by the Australian Competition and Consumer Commission.
Read MoreTag: SIG
Will Sigma’s proposal cure competition woes?
Shares in Sigma Healthcare (ASX:SIG) jumped more than 25% yesterday after the ACCC invited submissions. This was in relation to the pharmacy wholesaler's proposed court-enforceable undertaking regarding its $700+ million acquisition of Chemist Warehouse.
Read MoreOngoing merger expenses drive Sigma Healthcare’s 67% drop in profit
Pharmacy wholesaler and retailer Sigma Healthcare (ASX:SIG) says its significant drop in interim earnings is due to ongoing costs associated with the impending merger with retail chain Chemist Warehouse.
Read MoreSigma Healthcare shares drop amid ACCC concerns
Sigma Healthcare (ASX:SIG) shares fell more than 9% at one stage on Thursday after its proposed $8.8 billion merger with the massive Chemist Warehouse encountered potential competition issues with the key regulator, the ACCC.
Read MoreACCC raises competition concerns over Sigma Healthcare and Chemists Warehouse merger
The competition regulator, the ACCC, has raised questions about the planned $8.8 billion backward merger between Sigma Healthcare and Chemists Warehouse, citing ‘competition concerns’.
Read MoreChemist Warehouse to merge with Sigma Healthcare in $8.8 billion deal
Private-owned Chemist Warehouse is set to become an ASX 200 top company through its backward takeover of Sigma Healthcare (ASX:SIG), creating a company valued at an estimated $8.8 billion.
Read MoreSmall Profit, Even Smaller Payout for Sigma
Sigma Healthcare is paying a tiny half a cent per share final dividend after it slashed debt, boosted revenues and swung back to a small profit for the year to the end of January.
Read MoreSigma Pays Big Time for Lack of Direction
Investors in Sigma Healthcare reacted negatively to yesterday’s half year results, details of a major change in strategy and bare bones interim dividend to shareholders.
Read MoreSIG – Citi rates the stock as Neutral
The broker retains its Neutral rating and increases its target price to $0.52 from $0.50.
Read MoreSigma Ready to Put the Past Behind It
Despite a weak 2021-22 annual result, Sigma Healthcare believes it is in the final phase of its reboot and ready to show that it has overcome the problems that have been dogging it.
Read MoreSIG – Credit Suisse rates the stock as Neutral
The Neutral rating and target price of $0.53 are retained.
Read MoreSigma Ups Guidance on Rapid Antigen Test Demand
Pharmaceutical wholesaler Sigma Healthcare told the ASX on Wednesday that demand for Rapid Antigen Tests would push underlying earnings up 10% to 15% compared with last year.
Read MoreSIG – Citi rates the stock as Neutral
Citi lowers its target price to $0.50 from $0.60. The Neutral rating is unchanged.
Read MoreMarket Murmurs: SIG, BLD
Here are a couple of snippets in a weird old start to the week for the ASX from medical group Sigma Healthcare (ASX: SIG) and buidlng materials major Boral (ASX: BLD).
Read MoreAPI Chessboard Moves to a Stalemate
Sigma’s attempt to snatch control of API appears to have been thwarted, with rival bidder Wesfarmers exercising its call option over 19.3% API shares to put it in a dominant blocking position.
Read MoreSigma Leapfrogs Wesfarmers in Race for API
Sigma Healthcare has come over the top of Wesfarmers and made a non-binding cash and share offer for rival chemist Australian Pharmaceutical Industries that seems to have grabbed the lead in the battle.
Read MoreKathmandu, Sigma Feeling the Pinch
Outdoor retailer Kathmandu and pharmacy group Sigma have both given early hints of the damage the lockdowns since June have done to some retailers, with both reporting weak sales and earnings.
Read MoreMarket Shrugs Off Sigma CEO Loss
Sigma Healthcare shares took the loss of CEO Mark Hooper surprisingly well yesterday, given the surprise nature of the announcement and the lack of any real explanation.
Read MoreSigma Loses Long-Standing CEO
Last week it was AGL revealing the shock departure of its CEO. Today, Sigma Healthcare made the surprise announcement that CEO Mark Hooper will go after more than 10 years in the role.
Read MoreSigma Looking the Picture of Health
Sigma Healthcare has reported a $59 million net profit after tax for the year to January, much better than the $12.3 million loss for 2019-20.
Read MoreSigma Hits 2 1/2-year High on Forecast Bump
Shares in pharmaceutical wholesaler Sigma Healthcare hit their highest level in more than two and a half years yesterday after the company revealed a solid upgrade to expected earnings.
Read MoreNews Shorts: Kogan Flying, Qantas SPP Falls Flat, Sigma Slims Down
Another solid update from e-tailer Kogan, Qantas investors have given the airline the biggest thumbs down imaginable in rejecting help the company boost its liquidity while Sigma Healthcare has sold and leased back two of its Distribution Centres (DC’s) for $172 million, half the number of centres in the original deal.
Read MoreSIG – UBS rates the stock as Upgrade to Neutral from Sell
UBS estimates a combined earnings benefit of $8m for Sigma Healthcare from 2021 on the basis of the pharmacy wholesale funding in the seventh Community Pharmacy Agreement.
Read MoreEarnings News: Nufarm, Sigma, New Hope Coal
Three results including two from yesterday – from Nufarm and Sigma Healthcare – confirm that the figures are historical and useless for assessing the company’s outlook for the rest of the year and into 2021 in the wake of the impact of COVID-19.
Read MoreSIG – Credit Suisse rates the stock as Underperform
Sigma Healthcare has downgraded FY20 operating earnings (EBITDA) guidance to $46-47m. This comes as of result of reclaiming the FMCG portion of the Chemist Warehouse contract and given the necessity to reinvest in the business.
Read MoreSIG – UBS rates the stock as Downgrade to Sell from Neutral
Underlying earnings (EBIT) were ahead of guidance in FY19, although UBS notes earnings quality was affected by restructuring costs and weak cash conversion. The company has indicated FY20 underlying operating earnings (EBITDA) will be $55-60m.
Read MoreCan Sigma Find Growth Without Chemist Warehouse?
Shares in Sigma Healthcare resisted early selling pressure yesterday after the pharmaceutical and health group revealed slightly better than expected results for the 2018-19 financial year.
Read MoreSigma Rebuffs Aust Pharma Takeover
Sigma Healthcare (SIG) shares slumped 15% at one stage yesterday after rejected a half-hearted takeover offer from rival Australian Pharmaceutical Industries (API).
Read MoreRestructure costs halve Sigma profit
Shares in Sigma Healthcare slumped 11% after yesterday after the drugs supply group revealed the cost of cleaning up the company’s structure after losing the lucrative Chemist Warehouse supply contract.
Read MoreBitter Pill For Sigma As Chemist Warehouse Walks
Sigma Healthcare shares plunged 44% at one stage yesterday after it confirmed that it would not be continuing as a key supplier to the giant Chemist Warehouse chain in a new deal from July 1, 2019.
Read MoreBad Medicine Sees Sigma Profit Drop 10%
Lower sales amid a softer consumer environment plus the loss of a key customer saw Sigma Healthcare suffer fall in full-year underlying revenue and earnings for 2017-18 financial year.
Read MoreSigma In Good Health
Shares in pharmaceuticals and health products supplier Sigma Healthcare jumped more than 4% yesterday after the company met lowered guidance, revealed a new acquisition and reaffirmed it was on track for higher earnings in the next year.
Read MoreSigma Slammed On My Chemist Legal Battle
Shares in pharmaceuticals group Sigma Healthcare plunged almost 30% at one stage yesterday after the company revealed it had started legal action against My Chemist (MC), which owns the Chemist Warehouse (CW) brand.
Read MoreSigma Outlines Asian Expansion
Drugs distributor and pharmacy services firm Sigma Pharmaceuticals is one Australian company that should be poised to build on an already robust export performance into China following that country’s dramatic change of heart on e-commerce rules a week ago.
Read MoreSigma Upgrades Earnings Outlook
Surprise on the upside and you will be rewarded, even in a dodgy market like yesterday and its nasty near 1% plus sell off.
Read MoreSigma Upgrades H1 Earnings
Good news for shareholders at yesterday’s AGM of pharmacies supplier and drug distributor Sigma Pharmaceuticals (SIP) which says it is looking for a 10% jump in underlying earnings for the first half of 2016-17.
Read MoreSigma Earnings Slip
Sigma Pharmaceuticals lifted final dividend 50%, from 2 cents to 3 cents a share, despite warning of slowing earnings growth over the next two years.
Read MoreSigma Lifts H1 Profit 23%
SigmaPharmaceuticals is paying an interim dividend of 2 cents a share (none previously) after lifting underlying half year profit as it becomes less reliant on revenue from the Pharmaceutical Benefits Scheme (PBS).
Read MoreSigma Ups Dividend, Shares Jump
Sigma Pharmaceuticals’ (SIP) shares jumped 9.3% to 94c yesterday after the drugs wholesaler and distributor said earnings (EBIT) grew 11% before interest and tax in the year to January.
Read MoreSigma Sinks As Dividend Disappears
The market reaction to Sigma Pharmaceuticals’ (SIP) solid first half profit yesterday showed us one of the perils of being a no-dividend paying company.
Read More
